Release Date: March 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Did you say there is potential for in-licensing one asset in 2025 and another in 2026? A: Yes, that's our plan. We are looking at several assets, but business development doesn't always go exactly as planned. However, that is our overall strategy. - Phil Serwin, CEO
Q: Can you discuss the potential for Motixafortide in additional solid tumor indications and the maturity of business development discussions around that? A: We view PDAC as a prototype for other solid tumors. We are not investing more in PDAC currently due to ongoing collaborations that are low-cost. We hope for interim data in 2026, which could lead to business development discussions. - Phil Serwin, CEO
Q: Regarding the sale of Effexta, do they have any potential option on the solid tumor program? A: They do not have any option on the solid tumor program. - Phil Serwin, CEO
Q: How should we view the integration time within their program of Effexta and its impact on sales? A: We expect the transition to be seamless with no significant lag in sales. We are providing transition services and believe the integration will be smooth. - Phil Serwin, CEO
Q: Can you provide some color on the company's core competencies as you look to add potential assets to your pipeline? A: We have a highly experienced development team with capabilities from early-stage projects to approval. We also have cash flows from partnering arrangements and significant trials in PDAC ongoing at minimal cost. We are well-positioned to move forward. - Phil Serwin, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。